Hasan Ağın
Boston Children's Hospital
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Hasan Ağın.
Chest | 2008
Suna Asilsoy; Erhan Bayram; Hasan Ağın; Hurşit Apa; Demet Can; Saniye Gülle; Serdar Altinoz
Chronic cough in children is among the problems that lead to frequent consultations with a doctor. In this study, we attempted to research the reasons for chronic cough by an evaluation method using the guidelines that were suggested for children by the American College of Chest Physicians (ACCP) in 2006. We studied 108 children between 6 and 14 years of age who had a cough that lasted for > 4 weeks. The patients were reevaluated during the second to fourth weeks, and until either the cough terminated or resolved. Twenty-five percent of the patients received diagnoses of asthma and asthma-like symptoms, 23.4% received diagnoses of protracted bronchitis, 20.3% received diagnoses of upper airway cough syndrome (UACS), and 4.6% received diagnoses of gastroesophageal reflux disease. Asthma and asthma-like symptoms, protracted bronchitis, and UACS were detected in order of frequency as the reason for chronic cough in children. We concluded that the 2006 ACCP guidelines for the management of chronic cough in children are effective and can be successfully utilized in a nonaffluent study setting.
Indian Journal of Pediatrics | 2008
Hurşit Apa; Ertan Kayserili; Hasan Ağın; Murat Hızarcıoğlu; Pamir Gülez; Afig Berdeli
An offspring of marriage between two first cousins presented with atonic seizures developed on the 20th day of life. The physical examination of the case was normal. In laboratory results, Ca+2 level was 5,7 mg/dl, Mg+2: 0,4 mg/dl (1,3–2,1), PTH: 28,4 pg/ml (12–92), and P-: 4,5 mg/dl. The case was diagnosed as hypomagnesemia with secondary hypocalcemia (HSH) and TRPM6 gene mutation analysis revealed a homozygote mutation of E157X.
Indian Journal of Pediatrics | 2014
Hasan Ağın; İlker Devrim; Rana İşgüder; Utku Karaarslan; Esra Toprak Kanık; Ilker Gunay; Miray Kışla; Sultan Aydın; Gamze Gülfidan
ObjectıveTo determine the risk factors for developing candida infections in pediatric intensive care unit (PICU).MethodsThe present study was conducted as a case–control study and included the population of patients who were admitted to PICU during the period of March 2010–March 2011.ResultsDuring the study period, a total of 57 patients in PICU had candidemia, 4 cases were excluded due to their PICU stay less than 48 h and one due to the insufficient data. The most commonly isolated Candida species was C. albicans, followed by C. parapsilosis. The median duration of hospitalization in PICU was higher (22.0 d) in candidemia patients compared to control group (13.5 d) (p = 0.037). The patients with candidemia had higher rates of presence of mechanical ventilation, presence of central venous catheter, and being under total parenteral nutrition; compared to the control group.ConclusıonsThe longer PICU durations, mechanical ventilation, central venous catheter, total parenteral nutrition were the associated factors. Although trials for predicitive models or scoring systems for development of candidemia have been performed; more future studies were required for practical usage in clinics settings in order to prevent candidemia.
Nephrology | 2005
Durgul Ozdemir; Timur Meşe; Hasan Ağın; Sebnem Calkavur; Mustafa Bak
Background: The purpose of the present paper was to investigate the corrected QT (QTc) interval and QTc dispersion value, and the impact of haemodialysis on these parameters in children with chronic renal failure.
Pediatric Neurology | 2014
Rana İşgüder; Orkide Güzel; Hasan Ağın; Ünsal Yılmaz; Sanem Eren Akarcan; Tanju Çelik; Aycan Ünalp
BACKGROUND Levetiracetam has been proven to be effective in both partial and generalized seizures in children. However, few studies have reported its efficacy in the treatment of acute repetitive seizures. We aimed to investigate the efficacy and safety of levetiracetam in children with acute repetitive seizures. METHODS The medical records of children from the age of 1 month-18 years who received levetiracetam because of acute repetitive seizures in the pediatric intensive care unit between 2010 and 2013 were reviewed retrospectively. RESULTS Of the 133 patients, levetiracetam terminated seizures in 104 (78.2%). Side effects such as agitation and aggression were observed in three patients (2.2%). The likelihood of treatment failure was increased by four times by younger age at seizure onset; by six times in the individuals with neurological abnormalities; and by 22 times in the patients with West syndrome. The patients who used levetiracetam as the first treatment option for acute repetitive seizures had a longer duration of epilepsy, a higher rate of neurological abnormality, and a higher proportion of medically resistant epilepsy compared with the individuals who used levetiracetam as an add-on treatment to the other intravenous antiepileptic drugs. However, no differences were detected between these two groups in terms of treatment response. CONCLUSIONS Intravenous levetiracetam appears to be effective and safe in the treatment of acute repetitive seizures. Randomized clinical trials are needed to determine whether intravenous levetiracetam may replace other antiepileptic drugs as the first-line therapy in the management of acute repetitive seizures.
Pediatric Pulmonology | 2017
Rana İşgüder; Gökhan Ceylan; Hasan Ağın; Gamze Gülfidan; Yüce Ayhan; İlker Devrim
Our aim is to determine whether the presence of soluble triggering receptor expressed on myeloid cells‐1 (s‐TREM‐1) of bronchoalveolar lavage fluid (BALF), serum procalcitonin levels (PCT), and Clinical Pulmonary Infection Score (CPIS) have diagnostic value in children with VAP.
Journal of Tropical Pediatrics | 2016
Rahmi Özdemir; Rana İşgüder; Mehmet Küçük; Cem Karadeniz; Gökhan Ceylan; Nagehan Katipoğlu; Murat Muhtar Yilmazer; Yılmaz Yozgat; Timur Meşe; Hasan Ağın
OBJECTIVE To assess the feasibility of 12-lead electrocardiographic (ECG) measures such as P wave dispersion (PWd), QT interval, QT dispersion (QTd), Tp-e interval, Tp-e/QT and Tp-e/QTc ratio in predicting poor outcome in patients diagnosed with sepsis in pediatric intensive care unit (PICU). METHODS Ninety-three patients diagnosed with sepsis, severe sepsis or septic shock and 103 age- and sex-matched healthy children were enrolled into the study. PWd, QT interval, QTd, Tp-e interval and Tp-e/QT, Tp-e/QTc ratios were obtained from a 12-lead electrocardiogram. RESULTS PWd, QTd, Tp-e interval and Tp-e/QT, Tp-e/QTc ratios were significantly higher in septic patients compared with the controls. During the study period, 41 patients had died. In multivariate logistic regression analyses, only Tp-e/QT ratio was found to be an independent predictor of mortality. CONCLUSION The ECG measurements can predict the poor outcome in patients with sepsis. The Tp-e/QT ratio may be a valuable tool in predicting mortality for patients with sepsis in the PICU.
American Journal of Infection Control | 2016
İlker Devrim; Nevbahar Yaşar; Rana İşgüder; Gökhan Ceylan; Nuri Bayram; Nihal Özdamar; Nuriye Turgut; Yeliz Oruç; Gamze Gülfidan; İsmail Ağırbaş; Hasan Ağın
BACKGROUND Central line-associated bloodstream infections (CLABSIs) are among the most frequent health care-associated infections. Central line bundle (CLB) programs are useful for reducing CLABSIs. METHODS A retrospective study was designed to compare 2 periods: the prebundle and bundle periods. We evaluated the impact of a CLB including implementation of split-septum (SS) devices and single-use prefilled flushing (SUF) devices in critically ill children. RESULTS During the prebundle period, the overall rate was 24.5 CLABSIs per 1,000 central line (CL) days, whereas after the initiation of the CLB, the CLABSIs per 1,000 CL days dropped to 14.29. In the prebundle period, the daily cost per patient with CL and CLABSI were
Clinical Toxicology | 2013
Utku Karaarslan; Rana İşgüder; Özlem Bağ; Miray Kışla; Hasan Ağın; Nurettin Ünal
232.13 and
Expert Opinion on Pharmacotherapy | 2011
Ilker Devrim; Gamze Gülfidan; Ilker Gunay; Hasan Ağın; Baris Guven; Murat Muhtar Yilmazer; Ceyhun Dizdarer
254.83 consecutively. In the bundle period, the daily cost per patient with CL and CLABSI were